Comera Life Sciences Announces Process Exploring Strategic Alternatives
December 06 2023 - 7:30AM
Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the
“Company”), a life sciences company developing a new generation of
biologic medicines to improve patient access, safety, and
convenience, today announced that it has initiated a process to
explore strategic alternatives to maximize shareholder value.
As part of its process, Comera is exploring the potential for an
acquisition, company sale, merger, divestiture of assets,
licensing, or other strategic transactions and/or seeking
additional financing. There is no set timetable for this process
and there can be no assurance that this process will result in the
Company pursuing a transaction or that any transaction, if pursued,
will be completed on attractive terms. If the Company is unable to
complete a transaction, it may be required to seek a
reorganization, liquidation or other restructuring. The Company
does not expect to disclose or provide an update concerning
developments related to this process unless or until the Company’s
Board of Directors has approved a definitive course of action or
otherwise determines that other disclosure is necessary or
appropriate jurisdiction.
About Comera Life Sciences
Leading a compassionate new era in medicine,
Comera Life Sciences is applying a deep knowledge of formulation
science and technology to transform essential biologic medicines
from intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences’
mission, as well as the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of the federal securities laws.
These forward-looking statements generally are identified by the
words “believe,” “project,” “expect,” “anticipate,” “estimate,”
“intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
including statements related to the Company’s review and evaluation
of potential strategic alternatives and their impact on stockholder
value; the process by which the Company engages in evaluation of
strategic alternatives; the Company’s ability to identify potential
merger or acquisition partners; the Company’s ability to raise
capital to continue as a going concern; and the terms, timing,
structure, benefits and costs of any strategic transaction and
whether one will be consummated at all; and the impact of any
strategic transaction on the Company. These forward-looking
statements are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this document, including, but not
limited to: the results of our strategic review process; our
ability to raise capital; cash flow, cash burn, expenses,
obligations and liabilities; the interest of third parties in
entering into a merger, reverse merger, or other strategic
transaction with the Company; the outcomes of any litigation,
regulatory proceedings, inquiries or investigations that we may
become subject to; and other important factors discussed in the
Company’s filings with the Securities and Exchange Commission. If
we do not obtain additional equity or debt funding, our cash
resources will be depleted and we could be required to materially
reduce or suspend operations, which would likely have a material
adverse effect on our business, stock price and our business
relationships with third parties. If we do not have sufficient
funds to continue operations or satisfy our liabilities, we could
be required to seek a reorganization, liquidation or other
restructuring that could result in our stockholders losing some or
all of their investment in us. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Comera assumes no obligation and
does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Comera can give no assurance that it will achieve its
expectations.
Contacts
Comera Investor
John Woolford ICR Westwicke John.Woolford@westwicke.com
Comera Press
Jon Yu ICR WestwickeComeraPR@westwicke.com
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Dec 2023 to Dec 2024